ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
CROs and service providers at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
71 CROs and service providers are at ESMO 2026 — 49 presentations on the program and 46 with a booth in the exhibit hall. Most represented: Sarah Cannon Research Institute (10 on the program), IQVIA (3 on the program), MERIT CRO (2 on the program). 47 of them have their own page in this guide. As of Nov 2, 2026.
Tumour type
Top represented
Showing 1–10 of 71 organizations
| Organization | ESMO 2026 Attendance |
|---|---|
Sarah Cannon Research Institute Nashville, TN | |
Oncology research organization based in Nashville, Tennessee, running cancer clinical trials across a network of US community sites. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Satellite Fri Oct 23 18:45–19:00 Persistent Unmet Need in mUM: Limitations of Current Approaches Melanoma & skin cancers Abstract Sat Oct 24 10:25–10:35 Poster Sat Oct 24 12:00–12:45 Darovasertib and crizotinib for HLA-A*02–positive metastatic uveal melanoma: Results from the phase 2 OptimUM-01 study Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers Poster Sat Oct 24 12:00–12:45 Efficacy, safety, and biomarker analysis of DB-1310 (HER3-targeted ADC) in pretreated HR+/HER2- breast cancer: Updated global phase 1/2a trial Breast cancerBiomarkers & precision oncology Talk Sat Oct 24 14:45–15:05 Drugging the undruggables: The next wave of targeted therapies Biomarkers & precision oncology Talk Sat Oct 24 16:45–17:00 Next generation therapies Breast cancerBiomarkers & precision oncology Abstract Sun Oct 25 09:02–09:07 Abstract Sun Oct 25 10:15–10:20 Abstract Sun Oct 25 11:23–11:35 Invited Discussant LBA66, LBA67 and LBA68 Lung & thoracic cancers Poster Sun Oct 25 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 |
Global contract research and healthcare data company providing clinical trial services and real-world evidence. | Booth Exhibiting at Booth 1001 Poster Fri Oct 23 13:00–15:00 Optimizing first-line treatment in R/M head and neck cancer: Systematic review of prognostic, predictive, and effect modifying factors Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 THRIVE-20-PF Spanish validation and a stepwise framework for psychometric evaluation and benchmarking in oncology Gastrointestinal cancersNursing & supportive care Satellite Sun Oct 25 19:45–19:55 How Do Patient-Reported Outcomes Influence Reimbursement Decisions? Nursing & supportive care |
MC MERIT CRO Madison, WI | |
Contract research organization supporting clinical research. | Poster Fri Oct 23 13:00–15:00 Concordance and prognostic value of AI-assisted volumetric versus bidimensional RANO 2.0 assessment in glioblastoma: A comparative analysis Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 |
Cytel Geneva, Switzerland | |
Clinical trial design, biostatistics and data science services for oncology research. | Poster Fri Oct 23 13:00–15:00 |
Ipsos MORI London, United Kingdom | |
Market research and consulting company conducting healthcare research. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 |
L Lumanity London, United Kingdom | |
Healthcare consultancy providing evidence, consulting and communications services for life sciences. | Poster Fri Oct 23 13:00–15:00 Real-world treatment utilization in biomarker-positive cancer patients: Evidence from the Dutch PHARMO data network Gastrointestinal cancersGynaecological cancersBreast cancer Poster Fri Oct 23 13:00–15:00 |
SH Signant Health Blue Bell, PA | |
Clinical research technology and services company supporting clinical trials and patient outcome assessments. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 |
START Carolinas Myrtle Beach, SC | |
Oncology clinical research center conducting trials in prostate, bladder, and kidney cancers in Myrtle Beach, South Carolina. | Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Prognostic utility of circulating tumor cell (CTC) count, CTC conversion, and CTC0 in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC) Genitourinary cancersBiomarkers & precision oncology |
Global contract research organization headquartered in Ireland, providing clinical development and trial services. | Booth Exhibiting at Booth 8005 Poster Fri Oct 23 13:00–15:00 Automated RECIST 1.1 quality assessment in oncology trials: A proof-of-concept framework for discrepancy detection and anomaly scoring Lung & thoracic cancersMelanoma & skin cancers |
Contract research organisation providing clinical development services to biotech and specialty pharma companies. | Booth Exhibiting at Booth 8020 Poster Fri Oct 23 13:00–15:00 |
Find buyers from CROs and service providers
Tell us what you sell and we’ll find the people at these CROs and service providers most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse ESMO 2026 by
Organization type
Tumour type
Exhibit hall
Everyone
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction